Posts Tagged: stem cells

MaRS Innovation sponsoring Angels’ Den competition

Prima IP co-sponsoring the Ryerson University and St. Michael’s Hospital event When your business demands staying current with the newest inventions springing up across 15 academic members, keeping pace with what’s happening is half the challenge. That’s part of the reason why MaRS Innovation and Prima IP are sponsoring winners of an Angels’ Den competition involving the Institute for Biomedical Engineering, Science and Technology (iBEST). iBEST is a partnership between Ryerson University and St. Michael's Hospital that brings together Ryerson's engineering and science strengths ... Read more

Stem Cell Therapeutics Merger, Technology Featured in Biotechnology Focus

In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research. The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply. Here's a quote from Lawrence's article: “Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs ... Read more

Stem Cell Therapeutics licenses UHN’s Clinical Cancer Stem Cell Program

Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada. The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program. This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012. The initial consideration of $1.6 million for the UHN ... Read more

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto. The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program. This agreement produced a license for a UHN technology on April 17, 2013. (more…) Read more

ScarX Therapeutics Featured on Front Page of the Globe and Mail

MaRS Innovation's ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010. Read the article on Globe and Mail.com (note that depending on when you're accessing this page, the Globe's content may be subject to a pay wall). (more…) Read more

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions. “From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ... Read more

CIHR Commercialization Program funds insulin-alternative stem cell technology and nicotine addiction drug therapy

TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine addiction therapy from the Centre for Addiction and Mental Health (CAMH) - have received Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) funding. This funding – each grant is valued at $150,000 – is third party validation of MaRS Innovation’s approach to commercializing its members’ discoveries. The CIHR performs rigorous due diligence and ... Read more

MaRS Innovation selects Mount Sinai Hospital’s umbilical cord stem cell technology as first commercialization opportunity

TORONTO (June 29, 2009) – MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders. “With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Raphael (Rafi) Hofstein, President ... Read more